Can you provide the last earnings date for BIO-PATH HOLDINGS INC?
BIO-PATH HOLDINGS INC (BPTH) last reported earnings on 11/14/2024.
NASDAQ:BPTH • US09057N4097
Past quarterly earnings results for BIO-PATH HOLDINGS INC (BPTH), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q1 2025 | -0.40 | -0.39 | -3.20% | 91.80% | - | - | ||
| Q4 2024 | -0.38 | - | 94.65% | - | - | |||
| Q3 2024 | -0.70 | -1.04 | 32.72% | 89.06% | - | - | ||
| Q2 2024 | -1.16 | -1.57 | 26.15% | 89.06% | - | - | ||
| Q1 2024 | -4.88 | -4.63 | -5.38% | 63.03% | - | - | ||
| Q4 2023 | -7.05 | -5.51 | -28.00% | 32.21% | - | - | ||
| Q3 2023 | -6.40 | -6.94 | 7.73% | 34.69% | - | - | ||
| Q2 2023 | -10.60 | -10.61 | 0.08% | -26.19% | - | - | ||
| Q1 2023 | -13.20 | -9.18 | -43.79% | -40.43% | - | - | ||
| Q4 2022 | -10.40 | -9.18 | -13.29% | 11.86% | - | - | ||
| Q3 2022 | -9.80 | -9.28 | -5.58% | -68.97% | - | - | ||
| Q2 2022 | -8.40 | -10.10 | 16.82% | -61.54% | - | - | ||
| Q1 2022 | -9.40 | -9.28 | -1.27% | -9.30% | - | - | ||
| Q4 2021 | -11.80 | -6.53 | -80.76% | -3.51% | - | - | ||
| Q3 2021 | -5.80 | -6.73 | 13.84% | 63.75% | - | - | ||
| Q2 2021 | -5.20 | -8.06 | 35.47% | 52.73% | - | - | ||
| Q1 2021 | -8.60 | -10.10 | 14.83% | 52.22% | - | - | ||
| Q4 2020 | -11.40 | -15.91 | 28.36% | - | - | - | ||
| Q3 2020 | -16.00 | -16.93 | 5.50% | - | - | - | ||
| Q2 2020 | -11.00 | -18.16 | 39.41% | - | - | - | ||
| Q1 2020 | -18.00 | -13.67 | -31.69% | - | - | - |
Notes
BIO-PATH HOLDINGS INC (BPTH) last reported earnings on 11/14/2024.
BIO-PATH HOLDINGS INC (BPTH) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, BIO-PATH HOLDINGS INC (BPTH) has beaten EPS estimates in 2 out of 4 releases.